İstanbul, Turkey — Turkey’s pharmaceutical export champion World Medicine has signed an exclusive license and commercialization agreement with China-based innovator Bio-Thera Solutions to bring an ustekinumab biosimilar to the Turkish market. Under this agreement, World Medicine will hold the marketing authorization in Turkey and lead promotion and sales, while Bio-Thera will continue GMP-compliant manufacturing at its Guangzhou facilities.
With this strategic partnership, World Medicine aims to expand access to advanced treatment options for patients in Turkey living with immune-mediated diseases. The ustekinumab product—used in the treatment of Crohn’s disease—is expected to support broader therapeutic needs across additional indications, subject to local approvals and labeling.
Advancing patient access in immune-mediated diseases
Through the collaboration with Bio-Thera, World Medicine intends to further strengthen clinical options for adult patients, including those who are refractory, intolerant, or have contraindications to conventional therapies. In line with applicable regulatory guidance, the company plans to enable access to more advanced and effective treatments for conditions such as:
Executive commentary
Ruşen Kalender, Chairman of the Board at World Medicine, said: “From day one, we have worked to improve lives with a broad, high-quality portfolio. Our partnership with Bio-Thera is a natural extension of that mission. By delivering sustainable, high-standard solutions, we are taking an important step to make a critical therapy like ustekinumab available to patients in Turkey.”
Dr. Shengfeng Li, CEO of Bio-Thera, commented: “Bio-Thera is pleased to partner with World Medicine to commercialize our ustekinumab biosimilar in Turkey. We look forward to working together to bring this important medicine to patients.”
About World Medicine
Established in Turkey in 2011, World Medicine Pharmaceuticals Inc. is committed to enhancing quality of life worldwide by offering accessible and effective products through sustainable quality standards and an innovative approach. With a portfolio of 500+ pharmacological products spanning ophthalmology, neurology, endocrinology, cardiology, rheumatology, gastroenterology, urology, pulmonology, and more, World Medicine exports to 50+ countries and continues to invest to position Turkey as its primary production and strategic hub.
Learn more at worldmedicine.com.tr and follow us on X (@worldmedicinetr), LinkedIn (in/worldmedicineturkiye), and Instagram (@worldmedicineturkiye).
About Bio-Thera Solutions
Bio-Thera Solutions, Ltd. is a global, innovation-driven biopharmaceutical company headquartered in Guangzhou, China. The company researches and develops novel therapeutics for cancer, autoimmune, cardiovascular, ophthalmic, and other serious diseases, and also develops biosimilars to expand access to biologic therapies.
For more information, visit bio-thera.com and follow X (@bio_thera_sol), LinkedIn (in/bio-thera-solutions-ltd), and WeChat (Bio-Thera).
Disclaimer: This communication is intended for informational purposes only and does not constitute medical advice. Product availability, indications, and labeling are subject to Turkish regulatory approvals. Patients should consult their healthcare professionals for diagnosis and treatment decisions.